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Mass spccrromc(ry has been used IO provide insights into (hc mechanism of inhibition of cyslcinc proicascs by a hydroxylaminc dcrivaiivc. 
C13Z-Pl~c-Gly-NH-O-C0-(2.4.6-~le~)Pli. An oxidized form or papain rcsuhing from the incubmion of the cnzymc with 111~ pcplidyl hydro:.amatc 
in (bc ubscncc oT a reducing agem has been idcntificd as a sullinic acid. The prcscncc or a covalcn( enzyme-inhibiior complex of molecular mass 
consiswn( with a suirenmnidc adduce or tyapain could also bc dclcctcd by (his mcihod. lmplicalions on the mechanism o1’inacrivarion orcysicinc 
pro(e;rscs by peplidyl hydroxamalcs arc discussed. 
Cystcinc pro(c;rsc; Papnin; Pcplidyl hydroxamaw; OsiJa(ion: Inhibhion: Elcctrospray mass spcctromclry 
I. INTRODUCTION 
Because of their role in many biological processes and 
their pathophysiuiog~cal significance. cysleine proteases 
constitute prime targets for the design of specitic inhibi- 
tors [l-3]. A mtmber of compounds have been shown 
to irreversibly inhibit cysteine proteases, including 
chloro- and fluoromethyl ketones, acyloxymethyl 
ketones, diazomethyl ketones and pcptidyl cpoxides 
[l&6]. In recent years, d novel class of cysteine pro- 
tease inhibitors has been developed based on the hydro- 
xylamine function. Initially described as inhibitors of 
serine proteases [7], peptidyl hydroxamates have been 
shown to be much more effective inhibitors of cathepsin 
B and cysteine proteases in general l&9]. In particular, 
O-mesitoyl derivatives of peptidyl hydroxamates have 
been shown to be very potent inhibitors of cathepsin 5, 
with a second-order rate of inactivation comparable to 
those observed for chloromethyl ketone inhibitors [8]. 
It has been postulated that the inactivation mechanism 
could involve the formation of a tetrahedrai inter- 
mediate similar to that found in the pathway for sub- 
strate hydrolysis and that this intermediate could break 
down to form either a sulfcnamide or a thiolcarbamate 
[8]. More recently, the characterization by NMR of the 
complex formed between “C- and “N-labeled CBZ- 
Phe-Gly-NH-0-CO-(2,4,6-MeJPh and papain gives 
strong support for the sulfcnamide as the covalent in- 
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activation adduct of cysteine protcases by peptidyl hy- 
droxamate [IO]. In the same study, a competing inhibi- 
tion mechanism has been uncovered in the absence of 
a reducing thiol. The inactive enzyme formed in this 
process is not the sulfenamide nor a thiolcarbamate. 
However, the fact that part of the activity of the enzyme 
can be recovered by addition of DTT suggests some 
type of oxidation product of papain. 
111 the present work, we have examined the enzyme 
products formed by reaction of the cysteine protease 
papain with the peptidyl-O-acyl hydroxamate CBZ- 
Phe-Gly-NH-0-CO-(2.4,6-MQPh using the !echziquc 
of electrospray mass spectrometry [I 1,121. This techno- 
logy is still in its infancy but is proving to be very 
valuable for studying biological systems. Since ioniza- 
tion occurs under mild conditions at atmospheric pres- 
sure, enzymes and their derivatives are not fragmented. 
This method therefore allows determination of the mo- 
lecular masses of the papain products formed in the 
presence of the peptidyl hydrosamate. 
2. MATERIALS AND METHODS 
Papain was oblaincd f’rom Sigma Chemical Co. and was purilicd 
and aclivalcd as dcscribcd orcviouslv 113!. The inhibitor CUZ-Phc- 
Gly-NH-O-CO-(2.4.6.Mc,)T;h was p;eparfd as dcscribcd previously 
[8]. The subwatc CBZ-Phc-Arg-MCA was purchased t’rom IAF Bio- 
chcm International. LavaI. Qufbec. Samples For mass spcclromctric 
analysis were prcparcd by mixing cnzymc and inhibitor in a 20% 
acctonhrilc solmion. No buffer WI\S used for the mass spccrromclry 
expcrimen(s since they intcrferc with (he ionizalion process. Papain 
concentration was 40 PM and lhc pH was kept bewccn 5.5 and 6.5. 
ARcr adding ihc inhibilor. sullicicni time was allo\red Car formation 
oT Ihc inaclivc papain producis (dctcrmincd by measuring residual 
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Fig. !. (:I) The clcctrospmy nm.s spccIrun1 01’ papain. The zhsrgc 
SI~ICS ranging rrom I5+ IO ?I+ ilrc shown. (b)-(d) Perti;ll mass spectra 
01’ 1hc cnzymc 14oni Ihc I9+ charge-sIaIo region (rtriz = 1X0-1’80) in 
pr~scnc~ofv;lr~illfcoiicclltraiionsoTilic ilillibiIor CBZ-Phi-Gly-NH- 
0-CO-(X6-hls,)Ph ;inti in ~hc abxncc 01’:~ reducing Ihiol. The raiio 
of inhibitor owr cnzymc is I.0 (b). 4.9 (c). 10.0 (d) and 13,9(c). Peak 
assignmnI currcsponds IO Ihr: numbcrcd spccics in Fig. ?. Pcnks I b 
(23 454 3n) ml :! (23 777 Da) correspond lo ihc osidizud and sull’enii- 
;;iidc dcriwIiw 01‘ pzlp;Iin rcspcrIivcly. The peak idcnlilied as I b’ is 
probably dtw IO il sodium XILIUCI 01‘ osidizcd pilpilin (3 500 Da. 
papain 732 + 2 Nil). Olhcr minor peaks corrapond IO sodium and 
?;till;ilc ;IdducIs ol‘ p;ip;iin. ;IS dcscribzd in the IL‘XI. 
activhy ;qginr! ~hc wbstria CBZ-Phc-Arg-XXA). Prior 10 injection 
in the IXISS sp:ciromcIcr, ~hc sillnl1lc \V;is acitlilicd by ;Idding acid up 
10 il finill CO~IC~~1IriIliOll ol’ 20%. 
A lriplc qliildrtlpolc! milSs spL’cIronicIc!’ (111~’ API III LC/MS/MS 
S~SICIII, Scics, Thornhill. Oniario. C;I:li\diI). the dclililcd dzscriplion 
0Twhich h;lS ilpprilXd ~ISc\\.hcI.c [l4-161. \%I!+ used Ibr iill cxpcrimcnls. 
In bricl: ~hc II~~ISS SpccIromsIcr has ~III rrrl: (lll;lss-lo-ch;lrg~) range of 
O-2400 ;Ind islincd with iln ion-spray (piiculn;llicnlly-;Issisiud clccrro- 
spray) inwrfxc [Id]. Muhiply charged protein ions wcrc ycncr;l\cd by 
spraying \hc S;lmplC soltnion ihrough ;I slzinlcss-swl capill;iry held 
at ;I high powiial (-4-G kV). The sample soluIion was delivcrcd IO 
Ihc spmycr by ii syringe infusion punip (Model 12. H;lrv;lrd Appam- 
LUS, SouIh NaIick, MA. USA) lhrougli il fusctl silic;i cilpillilry of !OO 
,wn ID. The liquid flow ralc was set 211 I .O pllmin Tar s;unplc imrocluc- 
lion. The polrnli;il on Ihc sw-npling orifice oT ihc insIrumrnI WIS set 
at +35 V during calibr;lIion ;Intl was rilisrtl IO + I20 V for prolcins IO 
cnhilnc~ ion signills. TIIC inswmicni /II/Z SCillC WIS calibr;l\L’d with Ihc 
;mimonium iltldtlct ions or polypropylcnc glycol (PPG). The avcr;lgc 
Inolccuklr mass WlUCs ol’ 111c prowins wcrc cal;ula~ctl from the m/z 
p&s in ~hc charge distribulion profiles or the multiply charged ions 
[15.17.18]. 
3. RESULTS AND DISCUSSION 
Fig. la shows the elcctrospray mass spectrum obtain- 
ed for papain. It consists of a series of peaks corre- 
sponding to differenl III/L ratios of the enzyme from 
which a value of 23 431. (+ I) is obtained for the average 
lnolecular mass of papain (calculated from the amino 
acid sequence = 23 421 Da). Upon adding the hydroxa- 
niate inhibitor, shifts in the N/Z peaks are observed 
indicating the formation of papain products. This is 
illustrated for various ratios of inhibitor/enzyme in Fig. 
I b-e, where only the region of III/Z = 1220-l 280 (corrc- 
sponding to charge-state 19+) is shown. In the absence 
of a reducing thiol and at low inhibitor/enzyme ratios, 
the major peaks correspond to 23 454 (5 1) Da and 
23 500 (+ 2) Da (Fig. I b). The former is attributed to 
an oxidized form of papaiu (papain + 2 oxygens) while 
the latter is believed to correspond to a sodium adduct 
of the oxidized enzyme (papain + 2 0 + 2 Na’). Sodium 
as well as sulfate adducts are often observed using this 
technique [I91 and are present as niinor peaks in all 
~nass pectra obtained in this study. Gas phase collisio- 
nal activation has reduced the abu!ldance of these ion 
adducts. but is unable to remove them completely. 
At higher ratios of inhibitor/enzyme, another slgnif- 
cant peak appears in the mass spectrum (Fig. Ic-e). 
This is particularly evident in presence of 10.0 (Fig. Id) 
and 13.9 (Fig. le) equivalents of the peptidyl hydroxa- 
mate. The molecular mass calculated for this peak is 
23 777 (IL- I) Da, which can be attributed to compound 
2 in Fig. 2 (23 776 D;i calculated for 2). The mass spcc- 
trometry result alone cannot differentiate between the 
sulfenamidc and thiolcarbamate products since they 
have the same molecular mass. However. in combina- 
tion with previous NMR studies indicating the existence 
Enz-SH + CBZ-PheGly-NH-0-CO+,4,6-Me3)Ph 
(papain, 23422 Da) 
1 /” ‘. 
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[ Enr-iNHa] = Enz-SOH -- Enz-S02H 
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(papain + 16 Da) (papain + 32 Da) 
U ti 
Fig. 2. Proposed pIIIhw;lys ror rtilclion bctwcn p;ip;lin and CBZ-Phc- 
Gly-NI-I-O-CO.(2,4.6-hlc,)Ph. 
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Fig. 3. Partied mass spxlrum of papain (trr;: region 1220-1180). (a) 
In prcscncc of 13.9 cquivalculs or CBZ-Phc-Gly-NH-O-CO-(‘.4.6- 
Mc,)Ph and 2 mM DTT. Oxygen ws removed from ~hc cnzyrnc and 
inhibi!or sollllions by bubbling nitrogen bcrorc slarting ~hc rcnc:ian. 
Prak ~issignmcnls arc HS dcscribcd in Fig. I. (b) In lhc prcscncc of I. I 
equivalent or CBZ-Phc-Gly-NH-O-CO-(~.~.G-M~,)PII mid in lhc ab- 
scncc or DTT and oxygen (rmmovcd by bubbling nitrogcu in the 
solutions). Major peaks arc observed corresponding to molecular 
masses of 23 422 Da (I, rrcs papuin). 73 439 Da (Ia. sulrcnic acid). 
23 155 Da (I b, sulfinic acid) and 13 776 Da (1, sulrcnamidc). 
of a sul fenamide type compound [IO], the muss spectro- 
mctry result establishes convincingly that the species of 
23 777 Da observed at higher inhibitorlcnzyme ratios 
corresponds to compound 2. It must be noted however 
that in the absence of a reducing thiol. the oxidized 
species is still a major product even when a considerable 
excess of inhibitor is used. 
Fig. 3a shows the mass spectrum in the III/: 1220- 
1280 region of the inactivated form of papain (inhibitor/ 
enzyme ratio = 13.9j obtained in solutions where oxy- 
gen was removed by bubbling nitrogen and in the prcs- 
ence of 2 mM DTT. Under these conditions, the oxi- 
dized papain is not observed and on!y one species of 
23 777 Da corresponding to the enzyme-inhibitor ad- 
duct sulfenamidc (2) is formed. 
The existence of an oxidized form of papain was in- 
ferred from previous mechanistic studies of the inhibi- 
tion of papain by peptidyl 0-acyl hydroxamatc, but the 
structure of this product was unknown [IO]. It was prc- 
viously shown that 0-mcsitoyl hydroxylamine, an ex- 
pected turnover product, gives the same inhibitory ef- 
fect [IO], and it was proposed that this compound was 
the oxidant involved in this process. In fact. this reagent 
is known as an oxidant [20,21]. We propose that, based 
on the known chemistry of 0-acyl hydroxylamines [‘,O], 
the sulfcnamide Enz-S-NH, is initially formed in this 
process, but is rapidly hydrolyzed to give the su.lfenic 
acid Enz-S-OH (la in Fig. 2) and NH3 (previously de- 
tected as NHJ’ by “N-NMR [IO]). The sulfenic acid 
Enz-S-OH is expected to be a reactive species, readily 
reduced by thiol to give active enzyme [IO]. or air-oxi- 
dized further to give the more stable sulfinic acid Enz- 
S02H (lb) [22]. In the absence of DTT and oxygen. it 
should therefore be possibie to detect the Enz-S-OH 
species. To test this possibility, the spectrum of a 
papain-inhibitor solution under conditions where the 
oxidative inhibition is predominant (i.e. inhibitorlen- 
zyme ratio = I. 1 and in the absence of DTT) but where 
oxygen was removed by bubbling nitrogen, was mo- 
nitored (Fig. 3b). Three major peaks are observed of 
23 422 (+ I) Da (papain). 23 439 (+ I) Da (sulfenic acid 
la) and 23 455 (2 I) Da (sulfinic acid lb). The sulfcnic 
acid Enz-S-OH can indeed bc observed under those 
conditions. Since nitrogen bubbling cannot completely 
remove all traces of O,, the sulfinic acid lb is also pre- 
sent in solution. Fret papain is observed in the sample 
of Fig. 3b due to incomplete inactivation under those 
conditions. A small amount of the sulfcnamide adduct 
(2) is also observed. The molecular masses of the inac- 
tive forms of papain obtained in the absence of DTT 
(Figs. I and 3b) give strong support to the sulfenic and 
sultinic acids la and Ib (Fig. 3) as the oxidized papain 
species and to the model of Fig. 2 for the mechanism of 
papain inactivation by CBZ-Phe-Gly-NH-O-CO-(2,4.6- 
Me,)Ph. Such papain oxidation products have been 
proposed previously [23,24]. Our mass spectrometry rc- 
suits now provide evidence for papain sulfenic and sul- 
finic acids. 
III conclusion, the interaction of papain with pcptidyl 
0-acyl hydroxamatcs is a complex process involving 
two competing reaction pathways [IO], which affords 
different inactive enzyme products depending on the 
conditions. Evidence from a combination of NMR 
studies [IO] and clcctrospray mass spectrometry 
strongly indicates the formation of a novel sulfennmidc 
enzyme-inhibitor adduct 2 in the presence of reducing 
thiol. Mass spectrometry studies have provided 
evidence supporting the formation of papain sulfenic 
and sullkic acids (la and lb) in the absence of thiol, 
apparently formed via the action of the putative turn- 
over product O-mesitoyl hydroxylaminc [ IOj. Elec- 
trospray mass spectrometry is clearly an invaluable tool 
for the characterization of enzyme derivatives obtained 
from enzyme-inhibitor interactions. 
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